Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease
OBJECTIVES: This study examined the effectiveness of nirmatrelvir plus ritonavir (NMV-r) and molnupiravir (MOV) in treating COVID-19 among chronic kidney disease (CKD) patients.
METHODS: This retrospective cohort study, using the TriNetX research network, identified stage 3-5 CKD and end-stage kidney disease (ESKD) patients with non-hospitalized COVID-19 between 1 January 2022, and 31 May 2023. Propensity score matching (PSM) was used to compare patients on NMV-r or MOV (antiviral group) against those not receiving these treatments (control group). The primary composite outcome was the cumulative hazard ratio (HR) for all-cause hospitalization or death within the 30-day follow-up.
RESULTS: After PSM, two balanced cohorts of 6,275 patients each were established. The antiviral group exhibited a lower incidence of all-cause hospitalization or mortality (5.93% vs. 9.53%; HR: 0.626; 95% CI: 0.550-0.713) than controls. Additionally, antiviral recipients were associated with a lower risk of all-cause hospitalization (HR: 0.679; 95% CI: 0.594-0.777) and mortality (HR: 0.338; 95% CI: 0.227-0.504). The beneficial effects of antiviral agents were consistent across sex, age, vaccination status, antiviral type, and CKD stage.
CONCLUSION: Oral antiviral agents could be associated with lower rates of all-cause hospitalization or death among non-hospitalized COVID-19 patients with CKD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Expert review of anti-infective therapy - (2024) vom: 26. März, Seite 1-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Chia-Chen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 26.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/14787210.2024.2334052 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370152425 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370152425 | ||
| 003 | DE-627 | ||
| 005 | 20240327000340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240326s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14787210.2024.2334052 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM370152425 | ||
| 035 | |a (NLM)38525673 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Chia-Chen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a OBJECTIVES: This study examined the effectiveness of nirmatrelvir plus ritonavir (NMV-r) and molnupiravir (MOV) in treating COVID-19 among chronic kidney disease (CKD) patients | ||
| 520 | |a METHODS: This retrospective cohort study, using the TriNetX research network, identified stage 3-5 CKD and end-stage kidney disease (ESKD) patients with non-hospitalized COVID-19 between 1 January 2022, and 31 May 2023. Propensity score matching (PSM) was used to compare patients on NMV-r or MOV (antiviral group) against those not receiving these treatments (control group). The primary composite outcome was the cumulative hazard ratio (HR) for all-cause hospitalization or death within the 30-day follow-up | ||
| 520 | |a RESULTS: After PSM, two balanced cohorts of 6,275 patients each were established. The antiviral group exhibited a lower incidence of all-cause hospitalization or mortality (5.93% vs. 9.53%; HR: 0.626; 95% CI: 0.550-0.713) than controls. Additionally, antiviral recipients were associated with a lower risk of all-cause hospitalization (HR: 0.679; 95% CI: 0.594-0.777) and mortality (HR: 0.338; 95% CI: 0.227-0.504). The beneficial effects of antiviral agents were consistent across sex, age, vaccination status, antiviral type, and CKD stage | ||
| 520 | |a CONCLUSION: Oral antiviral agents could be associated with lower rates of all-cause hospitalization or death among non-hospitalized COVID-19 patients with CKD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a hospitalization | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a nirmatrelvir plus ritonavir | |
| 700 | 1 | |a Huang, Chi-Ya |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jheng-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Mei-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chuang, Min-Hsiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ting-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Ya-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Wan-Hsuan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Po-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ming-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Su-Yen |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Mei-Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Kuo-Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Chih-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, I-Ning |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anti-infective therapy |d 2003 |g (2024) vom: 26. März, Seite 1-8 |w (DE-627)NLM151540101 |x 1744-8336 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:26 |g month:03 |g pages:1-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14787210.2024.2334052 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 26 |c 03 |h 1-8 | ||